TWM
HRTX icon

TopTier Wealth Management’s Heron Therapeutics HRTX Stock Holding History

TopTier Wealth Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.8K Sell
25,350
-12,000
-32% -$9.62K 0.01% 133
2026
Q1 		$29.9K Buy
+37,350
New +$43.3K 0.02% 268

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

TopTier Wealth Management's HRTX Position: Q2 2026 in Review

TopTier Wealth Management reduced its Heron Therapeutics (HRTX) stake by 32% in Q2 2026, selling an estimated $9.62K and leaving 25,350 shares worth $10.8K. The position accounts for 0.01% of the portfolio, ranked #133.

TopTier Wealth Management first reported a position in HRTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $29.9K in Q1 2026. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • TopTier Wealth Management held 25,350 shares of Heron Therapeutics worth $10.8K as of Q2 2026.
  • TopTier Wealth Management sold 12,000 Heron Therapeutics shares in Q2 2026, an estimated $9.62K.
  • Heron Therapeutics made up 0.01% of TopTier Wealth Management's portfolio in Q2 2026, its #133 holding.
  • TopTier Wealth Management first reported a position in Heron Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • TopTier Wealth Management's Heron Therapeutics position peaked at $29.9K in Q1 2026.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on TopTier Wealth Management's 13F filing for Q2 2026, filed 14 Jul 2026.